Moderna (MRNA) Gross Profit (2020 - 2026)

Moderna (MRNA) has reported Gross Profit for 7 consecutive years, with $52.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Gross Profit rose 126.09% year-over-year to $52.0 million in Q2 2026; TTM through Jun 2026 was $521.0 million, a 67.76% decrease from a year earlier, with the FY2025 full-year figure at $1.1 billion, down 39.28% from the prior year.
• Gross Profit was $52.0 million for Q2 2026 at Moderna, up from -$566.0 million in the prior quarter.
• Over five years, Gross Profit peaked at $5.0 billion in Q1 2022 and troughed at -$566.0 million in Q1 2026.
• A 5-year average of $1.1 billion and a median of $226.5 million in 2024 frame the typical range for Gross Profit.
• Across the five-year window, Gross Profit jumped 428.78% in 2024 and sank 3244.44% in 2026, its largest moves.
• Over 5 years, Gross Profit stood at $4.7 billion in 2022, then slumped by 59.82% to $1.9 billion in 2023, then slumped by 87.94% to $227.0 million in 2024, then decreased by 0.44% to $226.0 million in 2025, then slumped by 76.99% to $52.0 million in 2026.
• The last three Gross Profit figures came in at $52.0 million (Q2 2026), -$566.0 million (Q1 2026), and $226.0 million (Q4 2025), per Business Quant data.